Klin Farmakol Farm. 2018;32(1):3-7 | DOI: 10.36290/far.2018.001

Prednisolone as a sample of the substance selected for Medical Literature Monitoring

Jaroslav Horký
Medistyl, spol. s r. o., Praha

Prednisolone belongs to most frequently reported substances in Medical Literature Monitoring (MLM) provided by EuropeanMedicines Agency since September 2015. The official list of MLM substances includes not only prednisolone, but also methylprednisoloneunder the item PREDNISOLONE. However in fact, introducing and classification of methylprednisolone under the itemof prednisolone is not careful and reliable and many relevant case reports are missing in MLM. On the contrary, some articleswith prednisone are incorrectly labelled under prednisolone. Concrete examples are given in this article.

Keywords: Medical Literature Monitoring, prednisolone, records analysis, pharmacovigilance, drug monitoring, methylprednisolone

Published: May 31, 2018  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Horký J. Prednisolone as a sample of the substance selected for Medical Literature Monitoring. Klin Farmakol Farm. 2018;32(1):3-7. doi: 10.36290/far.2018.001.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Detailed guide regarding the monitoring of medical literature and the entry of relevant information into the EudraVigilance database by the European Medicines Agency (http://www.ema.europa.eu/docs/en_GB/document_library/Other/2015/05/WC500186731.pdf)
    2. Horký J. Co přináší (a co nepřináší) české farmakovigilanci Evropská léková agentura v systému Medical Literature Monitoring. Klin Farmakol Farm 2017; 31(4): 3-7. Go to original source...
    3. Medical literature monitoring: updated substance and herbal substance groups (http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000633.jsp)

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.